11th CABA Annual Conference

BOSTON BIOFORUM 2018

CABA

2018波士顿生物医药论坛暨美中生物医药协会第11届年会

CATCHING THE WAVE

Trends and Disruptive Technologies in BioMedical R&D

与时俱进——探索颠覆性生物科技

Saturday, May 19th, 2018 | Boston Marriott Newton

11th CABA Annual Conference

BOSTON BIOFORUM 2018

CABA

2018波士顿生物医药论坛暨美中生物医药协会第11届年会

Time & Date: 8:00 am to 9:00 pm, May 19th, 2018

Venue: Boston Marriott Newton, 2345 Commonwealth Avenue, Newton, MA 02466

Theme: Catching the Wave: Trends and Disruptive Technologies in Biomedical R&D

Focus: Cell & Gene Therapy, Trends in Biomedical Research (Immuno-oncology, AI, Biologics), Investment across Borders, Career Path in US and China.

Chair

Bo Ying

Co-Chair

Ben Wei Lan Cao Jian Shao Carrie Liu

President

Kevin Fang

Committee Members

Carrie Yang	Chaoyang Dai	Dandan Ling	David Dai	Ellen Fan
Hao Cai	Jeannie Li	Jeff Hang	Jianyu Shang	Jianyu Shang
Jing Huang	Jo Lee	Li Xing	Liping Zhou	Liufang Hu
Pengyu Huang	Phil Zhang	Qingqing Cao	Ruiyi Dong	Sara Yin
Sherry Xiao	Shujia Dai	Weijia Wang	Winny Wang	Xiangyang Yu
Xiaohan Peng	Xue Shui	Youxin Zhang		

Pfizer

药明康德 WuXi AppTec

abpro THERAPEUTICS

BIOSYSTEMS Acro

ADESIS A Universal Display Company

Adlai Nortye 阿诺医药

AT ASTATECH

百济神州 BeiGene

百奥赛图 BIOCYTOGEN

biostage REGENERATIONS AHEAD

EISAI ANDOVER INNOVATIVE MEDICINES INSTITUTE (AIM) AiM WE MAKE MEDICINES

Eisai

FRONTAGE moving your compound forward

GenScript Make Research Easy

Harvard Pilgrim Health Care 哈佛格林健保

CrownBio CONNECTING SCIENCE TO PATIENTS

加科思 Jacobio

恒瑞

Medicilon

PerkinElmer For the Better

迈康升华 PharmaAdvance

Scilligence

TargetRx

TYGER

HUACELLS 华赛细胞

Wyzen WB Biosciences

YUROGEN Biosystems LLC

猎聘北美 LIEPIN NORTH AMERICA

nest.bio TALENT

Z-Park

SHENZHEN 深圳
North American Representative Office of Shenzhen, China
中国深圳市驻北美经贸代表处

QAKMONT SCRIPT 奥卡斯医药有限公司

SB Sino Biological Biological Solution Specialist

PharmaLegacy Preclinical Specialty Pharmacology Services

AGENDA

08:00 am - 09:00 am **REGISTRATION / SOCIAL & NETWORKING** (Conteniental Breakfast will be Provided))

09:00 am - 09:10 am **OPENING REMARKS**
Bo Ying, PhD, Conference Chair, President-Elect, CABA

09:10 am - 09:30 am **INTRODUCTION OF CABA**
Kevin Fang, PhD, President, CABA

SESSION I - CELL & GENE THERAPY
Moderator: *Lan Cao, PhD*, Executive Committee, CABA

09:30 am - 10:00 am Cellframe, A Revolutionary Organ Regeneration Platform
William Fodor, PhD, Chief Scientific Officer, Biostage

10:00 am - 10:30 am Meeting the Challenge of Manufacturing Advanced Therapies: Cell Therapies, Gene-Mediated Cell Therapies and Viral Vectors
Felix Hsu, MBA, SVP, Head of WuXi Advanced Therapies, Wuxi AppTec

10:30 am - 11:00 am The Enlightenment of Regenerative Medicine: Convergence of Evolutionary and Revolutionary Approaches
Chris Gemmiti, PhD, Co-founder and CEO, RedactBio, Inc.

11:00 am - 11:30 am Current and Emerging Innovation in Cell and Gene Therapy for Oncology
Paul E Juniewicz, PhD, Senior Director, Oncology Search & Evaluation, Center for External Innovation, Takeda Pharmaceuticals

11:30 am - 12:00 pm CRISPR/Cas9 – In Vivo and Ex Vivo Applications to Treat Genetic Diseases, Cancer and Autoimmunity
Birgit Schultes, PhD, VP of Immunology, Intellia Therapeutics Inc.

12:00 pm - 01:00 pm **LUNCH / VENDOR SHOW / CAREER FAIR**
CONCURRENT SESSION - CAREER DEVELOPMENT ROUND-TABLE

SESSION II – TRENDS IN BIOMEDICAL RESEARCH
Moderator: *Zhihong Chen, PhD*, VP of Biology, Adlai Nortye Biopharma Inc.

01:00 pm - 01:30 pm Enhancing First-in-Class Immuno-Oncology Drug Discovery Research & Development through Global Collaboration
Zhihong Chen, PhD, VP, Biology, Adlai Nortye Biopharma Inc.

01:30 pm - 02:00 pm Creating an Effective, AI-driven Company for Drug Development on the Cloud
Yide Alan Jiang, PhD, Chief Strategy Officer, Xtalpi Inc.

02:00 pm - 02:30 pm DNA Immunization to Elicit mAb against Challenging Targets
Shan Lu, MD, PhD, Professor, Department of Medicine, University of Massachusetts Medical School

02:30 pm - 03:00 pm **COFFEE BREAK AND VENDOR SHOW**

SESSION III - INVESTMENT ACROSS BORDERS
Moderator: *Ben Wei, PhD, MBA*, Executive Committee, CABA
John Xu, MD MBA,MS, SVP of Strategic Alliances, Abpro

03:00 pm - 03:30 pm From Entrepreneur to Investor: A Novel Way to Experience Inorganic Business
Johnson Zhang, MBA, Vice President & General Manager, Perkin Elmer APAC

03:30 pm - 04:00 pm Leveraging Collaboration and In Kind as Non-Dilutive Investments
Jae Sly, PhD, MBA, Director of Strategic Business Development, ACROBiosystems, Inc.

04:00 pm - 04:30 pm Venture Creation of Cross-Border Life Sciences Companies
Cheryl Cui, PhD, Founding Partner, Nest. Bio Ventures

04:30 pm - 05:00 pm Entrepreneurship From the US to China and Back, a Personal Journey
Alex Wu, PhD, MBA, Partner, Green Pine Capital Partners

05:00 pm - 05:30 pm Sailing Westward by China Biopharm Firms
Sean Fu, PhD, Vice President of Luye Global R&D, President of Luye Boston R&D

SESSION IV - DINNER RECEPTION

06:00 pm - 06:45 pm **KEYNOTE PRESENTATION:**
Tumor Profiling, CRISPR Screens, and Big Data Mining in Precision Cancer Medicine
Xiaole Shirley Liu, PhD, Professor of Statistics, Biostatistics, and Computational Biology, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health

06:45 pm - 07:30 pm **CABA AWARD CEREMONY & TEAM TRANSITION**

07:30 pm - 09:00 pm **SOCIAL AND NETWORKING**

SPEAKERS

William Fodor, Ph.D.
Chief Scientific Officer
Biostage

09:30 am-10:00 am Cellframe, a Revolutionary Organ Regeneration Platform

Bill Fodor was a founding scientist at Alexion Pharmaceuticals, where he served as an executive management team member and Senior Director of the Cell/Tissue Engineering, Transgenic Animal and Transplant Programs. He has also served as an Associate Professor at the University of Connecticut, Department of Molecular Cell Biology and the Center for Regenerative Biology, extending research areas into stem cells and stem cell engineering. Dr. Fodor was Senior Director of Product Development at ViaCell Inc., leading programs in hematopoietic stem cell process development and manufacturing, mesenchymal stem cell basic research and manufacturing for cardiac repair and pancreatic stem cell research. He was a consultant for the biotechnology industry, serving clients in stem cell research, gene therapy, stem cell manufacturing and stem cell genome engineering. Dr. Fodor has expertise in programs targeting transplant immunology, hematopoiesis, cardiac repair, stem cell potency, gene therapy for liver diseases, tissue engineering, design and oversight of pre-clinical non-GLP and GLP animal models and investigational New Drug Applications (Pre-clinical and CMC Modules). Dr. Fodor earned a PhD. in genetics from Ohio State University. He completed post-doctoral work at Yale University School of Medicine in the department of immunobiology, investigating the regulation of MHC class I and MHC class II genes in the histocompatibility complex.

Abstract
Biostage is a biotechnology company developing bioengineered organ implants to treat congenital defects, cancers and other life-threatening conditions of the esophagus, bronchus and trachea. The company's novel Cellframe™ technology utilizes an electrospinning process to produce a biocompatible mesh scaffold of known pore size and fiber diameter. Biostage's CellSpan Esophageal Implant (CEI) combines the Cellframe™ technology with stem cell biology to produce a bio-artificial tubular organ that stimulates the body's natural healing process, leading to the regeneration and restoration of organ function. A key feature of our technology is the development of a combination product (device + biologic), that effectively delivers the patient's own stem cells to the site of injury. The attractiveness of this combination product is the timed removal of the Cellframe scaffold after a short in-life time period, thereby allowing the patient's own cells to stimulate the regeneration process which proceeds in the absence of any foreign materials. An overview of Biostage's product development strategy and the status of our lead program will be discussed.

Felix Hsu, MBA
SVP and Head of WuXi Advanced Therapies
Wuxi AppTec

10:00 am-10:30 am Meeting the Challenge of Manufacturing Advanced Therapies: Cell Therapies, Gene-mediated Cell Therapies and Viral Vectors

Felix Hsu is the Senior Vice President and Head of WuXi AppTec's Advanced Therapy business which is a new business unit. The Advanced Therapy business is focused on providing integrated manufacturing and testing services for companies in cell therapy, gene therapy and editing, and other newer technologies. WuXi has provided cell therapy manufacturing since 2004, and over the last 4-5 years has invested significantly in building out manufacturing and testing capabilities for Advanced Therapies customers.
Prior to running this business, Felix spent 8.5 years as the SVP and Head of the WuXi AppTec's US Business Unit which included Medical Device and Biologic testing services and Advanced Therapy testing and manufacturing. Felix's career also includes over 20 years of experience at other medical device and pharmaceutical companies. At Medtronic, key roles Felix had included the following: VP for Global Supply Chain, VP and GM for Cardiac Surgery in Asia Pacific, VP President of Process Improvement for Cardiac Surgery, and Global Head of Marketing for Medtronic Heart Valves. At Abbott Laboratories Felix had a number of positions in sales, marketing and strategic planning.
Felix attended General Motors Institute (today know as Kettering University) where he received his Bachelors of Science degree in Electrical Engineering. Felix later attended the University of Michigan and received an MBA degree.

Abstract
Advanced Therapies represent the next wave in therapeutic treatment options. Some are potential cures and others can be potential treatment options for current unmet needs, especially in orphan diseases. There are many different types of cell and gene therapies. The market is emerging, and in its current state, there are many challenges to the manufacturing of these products.

This presentation will discuss some of the manufacturing challenges including the following:

* Management of autologous products
* Product consistency
* Lack of infrastructure in the industry

It will also discuss what WuXi is doing to help address some of these industry challenges.

Chris Gemmiti, Ph.D.
Co-founder and CEO
RedactBio, Inc.

10:30 am-11:00 am The Enlightenment of Regenerative Medicine: Convergence of Evolutionary and Revolutionary Approaches

Chris Gemmiti has 20+ years' experience in the cell and gene therapy arena, and is the CEO of RedactBio Inc., a gene editing and tissue engineering start-up, creating human skin for acute wounds. He is also VP of Operations at Sentien Biotech, a clinical-stage company using mesenchymal stem cells in a bioreactor to treat systemic inflammatory diseases and acute organ failure. Previously, Chris had roles at Harvard University and at Organogenesis, the latter at which he led the approval of the first CBER-approved allogeneic cell therapy in 2012. Chris has his PhD in Biomedical Engineering from Georgia Tech.

Abstract
Over the past 30 years, the regenerative medicine and tissue engineering industry has gone through the prototypical "hype cycle" of emerging technologies. Having survived the inflated expectations and crash of the early 2000's, cell and gene therapy has become an enlightened and productive industry. This progress is attributable to the evolution of process development, manufacturing optimization and refined business planning, which is now converging with breakthrough science and clinical progress in gene therapy, gene editing and immune-engineering. An overview the industry's progress will be presented, along with some examples of new, innovative visions.

Paul E Juniewicz, Ph.D.
Senior Director, Oncology Search & Evaluation, Center for External Innovation
Takeda Pharmaceuticals

11:00 am-11:30 am Current and Emerging Innovation in Cell and Gene Therapy for Oncology

Paul E Juniewicz was born in Jersey City NJ and educated at Rutgers University NJ (BS), North Carolina State University, NC (MS / PhD) and Johns Hopkins University, MD (Post-doctoral training).
Paul started his professional career with Sterling Drug as a bench research scientist and then took a position as Oncology Project Manager overseeing several oncology projects. Following the acquisition of Sterling Drug by Sanofi, Paul rose to the role of VP Oncology Project Management overseeing the development of several key oncology projects that resulted in global regulatory approvals for several agents including oxaliplatin & aflibercept for colorectal cancer & rasburicase for tumor lysis syndrome.
Following the merger and acquisition with Aventis by Sanofi, Paul then took a brief role as Head Global External Innovation at Sanofi-Aventis before returning to the oncology space and relocating in Cambridge MA as Head of Oncology Search and Evaluation.
In April 2015, Paul took a position with Takeda Pharmaceuticals in Cambridge MA as Senior Director responsible for Oncology Search & Evaluation. In this role, Paul has been involved with several transactions including the research collaborations with Shattuck Labs, Molecular Templates, Maverick, among others, the Japan licensing of cabozantinib (Exelixis) and niraparib (Tesaro) as well as the merger and acquisition of Ariad Pharmaceuticals.

Abstract
With the advent of targeted therapy and immune-oncology as validated approaches for cancer therapy, the use of living cells, specifically targeted immune cells, for cancer treatment in patients that have exhausted all other treatment options has also recently emerged as an innovative approach. Various methods of cancer cell therapy, such as Chimeric Antigen T-cell Receptors (or CARTs), T-cell Receptors (TCRs) and Tumor Infiltrating Lymphocytes (TILs) treatment will be discussed in this presentation, together with their unprecedent clinical outcomes, particularly in patients with refractory / relapsed hematological cancers. Use of cell therapy as a cancer treatment modality has necessitated innovation in several areas of drug discovery and drug development including genetic modification and manufacturing of living cells, clinical treatment paradigms and regulatory development paths, in order to maximize the potential of using living cells or cell therapy as a viable and feasible therapeutic option for cancer patients.

Although use of CART therapy for cancer treatment was primarily developed in USA, there has been an explosion of this field in China so that today, the number of clinical programs in the CART area for China equals that of USA and greatly exceeds the number of programs in Europe or other parts of the World.

Further innovations in CART design and construction, genetic modification of cells, manufacturing, clinical study designs, regulatory paths for approval, commercial models as well as patent / intellectual property will be required to maximize the potential of using living cells or cell therapy as a viable and feasible therapeutic option for cancer patients.

Birgit Schultes, Ph.D.
VP of Immunology
Intellia Therapeutics Inc.

11:30 am-12:00 pm CRISPR/Cas9 – In Vivo and Ex Vivo Applications to Treat Genetic Diseases, Cancer and Autoimmunity

Birgit Schultes, Ph.D. is Vice President, Immunology at Intellia, where she has served since September 2017. In this capacity, she provides leadership and direction to build out Intellia's ex vivo CRISPR programs and is responsible for the generation of next-generation engineered T cells for oncology and autoimmune indications. Previously, she was Senior Director In Vivo at Unum Therapeutics, bringing 3 ACTR T cell development candidates into the clinic within her 2-year tenure. Prior to Unum, Dr. Schultes held positions of increasing R&D strategic and operational responsibilities at Momenta Pharmaceuticals and United Therapeutics, working on monoclonal antibody, vaccine, and heparin derived drug candidates as well as biomarkers for a variety of cancer indications. Dr. Schultes holds a Master of Science degree in Cell Biology and a Ph.D. in Immunology from the University of Bonn, Germany.

Abstract
The CRISPR/Cas9 technology is a novel powerful technology with aspirations to cure rare genetic diseases via in vivo elimination or repair of mutated proteins or ex vivo edited cell therapy products replacing the normal cell functions after adoptive transfer. Ex vivo editing of immune cells or induced pluripotent stem cells hold great promise to restore failing cellular functions or regenerating them with cells from healthy allogenic donors. Examples will be provided on in vivo editing of hepatocytes using an LNP delivery system for the treatment of Transthyretin Amyloidosis (ATTR), showing that single and repeated treatments are feasible and result in long-term reduction in the targeted enzyme in mice, rats and non-human primates. Ex vivo applications in HSCs can for example restore normal erythrocyte function in Sickle Cell Anemia by CRISPR/Cas9 mediated reactivation of the fetal hemoglobin gene. Engineered CAR-T and TCR-transgenic T cells, including the development of such cells from healthy universal donors, can address unmet needs in hematological and solid tumors, while stable engineered regulatory T cells have promise in severe and difficult to control auto-immune diseases.

Zhihong Chen, Ph.D.
VP, Biology
Adlai Nortye Biopharma Inc.

01:00 pm-01:30 pm Enhancing First-in-Class Immuno-Oncology Drug Discovery Research & Development through Global Collaboration

Dr. Zhihong Chen currently serve as VP biology at Adlai Nortye Biopharma, responsible for the biology and pharmacology of the company in Hangzhou and also heading the R&D Center in Boston, USA.
Zhihong has more than 20 years of cancer research and oncology drug R&D experiences in academic and biopharma industry. Previously, Zhihong worked at Eisai (Andover, MA, USA) for more than 10 years, with increasing roles and responsibilities across several function departments, from target identification and assay development, molecular and cellular pharmacology to Oncology Product Creation Unit, mainly focusing on new oncology drug discovery and development. During his career at Eisai, Zhihong has co-led several oncology discovery programs responsible for the biology efforts of those projects, some of which advanced into clinical trials. As a core IPT (International Project Team) member of the clinical trial team of the project, Zhihong experienced the whole drug R&D process from discovery to early clinical trial. Working together with the clinical team, contributed to the Phase 1/2 clinical trial protocol preparation and planning through pharmacology and biomarker studies providing pre-clinical concepts to recommend potential indications, combination strategies, biomarker strategy to aid patient selection.
Zhihong received a Bachelor degree from Chemical Engineering department and a Master in Biochemical Engineering from East China University of Science and Technology. He got his Ph.D. in Molecular and Cellular Biology from The University of Tokyo Graduate School of Medicine. He received postdoctoral training at Harvard University.

Abstract
Cancer immunotherapy particularly PD-1/PD-L1 antibody-based therapies have made significant impact on the treatment of cancer patients. PD-1/PD-L1 inhibition has demonstrated remarkable anti-tumor activity in a broad spectrum of solid and hematological malignancies, leading to regulatory approval of an increasing list of agents in a growing number of cancers. However, despite the remarkable clinical efficacy in a number of cancers, it has become clear that they are not sufficiently active for most patients. The clinical efficacy of PD-1/PD-L1 pathway inhibition as monotherapy has been limited to a subset of patients, with response rates of roughly 20% in many cancers. While predictive biomarkers such as PD-L1 expression on tumor and immune cells, or mutational/neoantigen load, may allow enrichment of patient populations, combination therapies will likely be required to enhance the anti-tumor activity of immune checkpoint inhibition. The combination strategy will be discussed.

Further innovations in CART design and construction, genetic modification of cells, manufacturing, clinical study designs, regulatory paths for approval, commercial models as well as patent / intellectual property will be required to maximize the potential of using living cells or cell therapy as a viable and feasible therapeutic option for cancer patients.

Yide Alan Jiang, Ph.D.
Chief Strategy Officer
XtalPi Inc.

01:30 pm-02:00 pm Creating an Effective, AI-Driven Company for Drug Development on the Cloud

Dr. Jiang as Chief Strategy Officer of Xtalpi Inc. is responsible for the company's strategy development including identification of growth opportunities, strategic planning and execution. He joined Xtalpi in 2015 bringing over fifteen years of scientific and research management experience, most of it gained in positions of increasing responsibility at Genzyme and then Sanofi-Genzyme. His early tenure at Genzyme was in disease biology research focusing on oncology and genetic diseases. Following Sanofi's acquisition of Genzyme in 2011, Dr. Jiang was appointed as liaison and director of Asia R&D Strategy of the Sanofi-Genzyme R&D Center and in that capacity he was responsible for the development of Genzyme Asia/China R&D strategy and led cross-functional R&D external collaborations and projects in Asia. He was also a key member of the Translational Medicine team and focused on strategic implementation of pharmacogenomics and biomarker in early clinical development.
Alan received his medical degree from Shanghai Medical University (Fudan University) and doctorate in molecular biology from the University of Tennessee at Memphis, followed by post-doctoral research in hematology and oncology at Brigham & Women's Hospital, Harvard Medical School.

Abstract
Machine learning (ML)/artificial intelligence (AI) has emerged as a potential solution to strategically reduce time and expense in R&D expenditures to bring a new pharmaceutical drug to market. Recently, advances in computer technology and modeling combined with organic crystal structure prediction (CSP) has attracted attention from the pharmaceutical industry due to the importance of solid-state structures and properties in the drug development process. The pioneer innovative CSP technology as part of XtalPi's Intelligent Digital Drug Discovery and Development (ID4), which deploys a combination of ML/AI, quantum physics algorithms and cloud high performance computing will be introduced. How XtalPi integrated its CSP technology into drug design and pharmaceutical product development in collaboration with industry partners will be presented.

Shan Lu, MD, PhD
ISV board member and previous president (2011-2013)
Director, Laboratory of Nucleic Acid Vaccines
Professor, Department of Medicine
University of Massachusetts Medical School, USA

02:00 pm-02:30 pm DNA Immunization to Elicit mAb against Challenging Targets

Dr. Lu is a physician scientist and a leading expert in novel vaccine development. Currently he is a tenured professor and Director of Laboratory of Nucleic Acid Vaccines in Department of Medicine at the University of Massachusetts Medical School, USA.
Dr. Lu was a Howard Hughes Physician Research Fellow in his early career and has been a board certified attending physician for the last two decades. He is a Fellow of American College of Physicians (FACP).
Dr. Lu's research interests are in the development of novel vaccines against emerging infectious diseases and biodefense targets. He was one of the pioneers in developing DNA vaccine technology and has applied this technology to developing a polyvalent DNA prime-protein boost HIV vaccine which showed high immunogenicity in human studies including broadly cross-reactive antibodies. He has also used DNA immunization to generate highly functional monoclonal antibodies from mice, rabbit and healthy human volunteers against a wide range of infectious disease and non-infectious disease targets.
Dr. Lu is a member of the Executive Board of International Society for Vaccines (ISV) since 2008 and served as ISV's President from 2011-2013. He is a Fellow of ISV (FISV). He is a member of the Editorial Boards for Journal of Virology, Vaccine, Nature's NPj-Vaccines among other journals in related fields. He is the founding Deputy Editor-in-Chief for Emerging Microbes and Infections, published by Nature Publishing Group (NPG). Dr. Lu has co-authored over 200 research papers and chapters. He is also an Honorary Professor of Fudan University and the Chair of International Scientific Advisory Committee for China's National Engineering Laboratory of Therapeutic Vaccines.

Abstract
The discovery of DNA immunization in early 1990s was truly a landmark in the history of vaccinology. Its applications have greatly expanded in the last several decades. In particular, better understanding on the impact of DNA delivered antigen presentation and processing to the development of antigen-specific B cell responses has led to the use of this approach to elicit not only high quality antibody responses in vaccines but also the functional monoclonal antibodies (mAbs) for therapeutic applications. This approach is particularly powerful in the development of mAbs against challenging targets – a major obstacle in the next phase anti-tumor immune therapy.

Johnson Zhang, MBA
Vice President & General Manager, Perkin Elmer APAC
Perkin Elmer APAC

03:00 pm-03:30 pm From Entrepreneur to Investor: a Novel Way to Experience Inorganic Business

Mr. Zhang joined PerkinElmer in September 2009 when PerkinElmer acquired Shanghai Xinbo Biotechnology Co., Ltd. as the chairman and general manager of Xinbo Bio. In October 2009, Mr. Zhang was appointed as the Vice President of Genetic Screening and the General Manager of Asia Pacific. In May 2010, in order to open up more diagnostic business opportunities in emerging markets, Mr. Zhang began to be Vice President of Emerging Diagnostics (GM) and General Manager of newly formed Asia Pacific Region; since June 2011, Mr. Zhang has been the Vice President of Diagnostic Division and General Manager of Asia Pacific, and is responsible for the entire Asia-Pacific region of PerkinElmer Diagnostics.
Prior to joining PerkinElmer, Mr. Zhang founded Xinbo Life as a founder in 2000 and has served as chairman and general manager. Xinbo Bio successfully developed China's first time-resolved fluorescence detection system and in vitro diagnostic kit. It has applied time-resolved technology to the detection of infectious diseases such as liver disease for the first time in the world, and has been widely used in more than one thousand secondary and tertiary level hospitals in China. The project won the second prize of 2003 National Science Progress Award.
Mr. Zhang Jun holds a master's degree in business administration from the China Europe International Business School. He previously obtained a bachelor's degree in mathematics from Fudan University.

Abstract
As first generation entrepreneur in China diagnostics industry, Johnson will bring the story about the M&A happened to his startup and from his employer, Perkin Elmer. Given his unique experience, from entrepreneur to executive leader, he will also share his prospective of cross-board investment.

Jae Sly Ph.D., MBA
Director of Strategic Business Development
ACROBiosystems, Inc

03:30 pm-04:00 pm Leveraging Collaboration and In Kind as Non-Dilutive Funding

Jae Sly is the Director, of Strategic Business Development and Innovation Lab Operations for ACROBiosystems. Jae has over 20 years in the Biopharmaceutical Industry, from R&D to Clinic. Jae is an Industry Leader providing strategic partnering of Biopharma technologies and services. One such technology, implemented innovation that launched single-use manufacturing. Jae has initiated cross border partnering platforms, investment forums and is a corporate mentor in the Delaware and Maryland Incubator Startup Programs for Entrepreneur Professional Series. Collaborations, Contract negotiations and technology evaluations for Investment Opportunities, has been primary expansion within Jae's portfolio of services in last several years. Jae maintains a strong Industry presence by presenting and attending at major conferences. Jae received her Ph.D. in Immunology from University of Washington and MBA from San Diego State University. Jae is a member of LES, ICOY, ESACT and BIO.

Abstract
Investment opportunities in a New Company or Technology are very exciting! Few aspiring business founders want to talk about the less “exciting” parts of the process, like when and how to get non-dilutive capital. But I have also learned that understanding the “boring” stuff almost always makes a big difference in outcomes.
Failure to know when and how to get non-dilutive capital can mean the loss of millions of dollars in profits going into the pocket of an entrepreneur and partners. Leveraging opportunities for collaborations, the potential of In Kind and other creative methods can lead to great success and stronger relationships with your Investors.

Cheryl Cui, Ph.D.
Founder Partner, Nest.Bio Ventures
Nest.Bio Ventures

04:00 pm-04:30 pm Venture Creation of Cross-Border Life Sciences Companies

Cheryl Cui is the founding partner of Nest.Bio Ventures, a Cambridge-based venture creation and venture capital firm focused on leveraging technological breakthroughs to develop, fund, and commercialize next-generation therapeutics globally, especially across North America and China. Before Nest.Bio, Cheryl was a Venture Partner at VentureHealth, where she led multiple successful deals in the biotechnology and medical device markets.

Before entering venture capital, Cheryl co-founded a mobile health company that facilitates chronic disease management, which was acquired in 2012, and was selected as one of Canada's "Next 36" top entrepreneurs.

Cheryl received her joint Ph.D. degree from the Harvard-MIT Health Science and Technology Program, and her B.A.Sc. in Biomedical Engineering at the University of Toronto. Her research has led to multiple first-author publications in top journals, including Science, Nature Nanotechnology, and PNAS.

Abstract

Nest.Bio is a life sciences venture development and venture capital firm focused on leveraging technological breakthroughs to develop, fund, and commercialize next-generation therapeutics globally. We will discuss the challenges and opportunities in building cross-border biotech companies and the expertise needed across the spectrum.

Alex Wu, Ph.D., MBA
Partner
Green Pine Capital Partners

04:30 pm-05:00 pm Entrepreneurship from the US to China and back, a Personal Journey

As its co-founder and CEO from inception to IPO in 10 years, Dr. Alex Wu helped to build Crown Bioscience into a global leading provider of drug discovery and development solutions for biotech and pharmaceutical partners. With operations in the US, China and UK, the company counts 18 of the top 20 leading global pharmaceutical and over 500 biotech companies and academic institutions as customers. The company was acquired for over $400 million by JSR in December 2017.

Before Crown Bioscience, Dr. Wu was the Chief Business Officer of Starvax International, a development stage biotech company specialized in oncology and infectious diseases. Prior to Starvax, Alex was with Burrill & Company, a leading life sciences venture capital firm in San Francisco. Before joining the venture capital industry, Alex was involved in several start-ups, one of which was Unimicro Technologies, Inc., an analytical instrumentation startup. He also worked for Hoffmannn-La Roche as Manager of Business Development and Strategic Planning.
Alex received B.S. in Biochemistry from Fudan University in Shanghai and Ph.D. and MBA from the University of California, Berkeley. He conducted post-doctoral research at Stanford University.

Abstract
Alex intends to share with the audience his personal experience in founding Crown Bioscience in the Silicon Valley, building its China operations and expanding it into a global presence. Now that the company is being acquired, he is back in the US. It is his hope that by leveraging his entrepreneurial experience and industry network, and together with venture capital, he could help entrepreneurs build their startups into successful enterprises.

Xiyong Sean Fu, Ph.D., MBA
Vice President of Luye Global R&D, President of Luye Boston R&D
Luye

05:00 pm-05:30 pm Sailing Westward by China Biopharm Firms

Dr. Xi-Yong Fu is the Vice President of Luye Global R&D, President of Luye Boston R&D LLC.
As a part of Luye's global R&D network, Boston R&D Center is responsible for developing innovative biologics assets and novel drug delivery technologies. Under the leadership of Dr. Fu, Luye Boston R&D Center has emerged as one of preeminent R&D centers in US established by a China biotech company.
Prior to joining Luye, Dr. Fu was the President of Cureport Inc. Before that, Dr. Fu worded at Merck & Co., for 15 years with a wide range of responsibilities covering R&D, business development, finance and operational management.
Dr. Fu is an experienced business professional. He managed the finance of a $300M late stage clinical portfolio at Merck. He led the network integration after the landmark $42B merger between Merck and Schering. His work directly impacted 22 global sites and over 6000 scientists.
Dr. Fu is a passionate scientist. Over years, Dr. Fu directly contributed to over 15 preclinical development programs including the HIV integrase inhibitor Isentress® which has since become a pillar in HIV treatment with an annual global sale over $1.2 billion.
Dr. Fu is an active member of the biotech community at large, serving as the President of Sino-American Pharmaceutical Professionals Association – Greater Philadelphia (SAPA-GP) between 2014 and 2015 and as SAPA Executive Committee member between 2012 and 2017.
Dr. Fu is an honorable recipient of the Best Business Value Award by Merck Research Laboratories; the Research Gold Award by Materials Research Society (MRS) and the prestigious William Oxley Thompson Award by The Ohio State University.
Dr. Fu earned his PhD from The Ohio State University and his MBA from the Wharton School of Business.

Abstract
There have been few industries in history that have the profound impact on human lives as the Biopharmaceutical industry in the 21st century. Driven by the clinical successes of immuno-oncology, the industry is translating basic sciences into clinical practices at an unprecedented rate. In the meantime, China's biotech industry continues to mature and has become an important global player. Increasing number of Chinese companies are opening up operations in US, many in the Boston area. What can we learn from their experiences? What can we expect from this approach? What are the challenges for Chinese companies in the process toward globalization? I will share some thoughts and experiences along those lines.

Xiaole Shirley Liu, Ph.D.
Professor of Statistics, Biostatistics, and Computational Biology
Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health

06:00 pm-06:45 pm **[KEYNOTE]**
Tumor profiling, CRISPR Screens, and Big Data Mining in Precision Cancer Medicine

Xiaole Shirley Liu received PhD in Biomedical Informatics and PhD minor in Computer Science from Stanford University. Her research focuses on algorithm development and integrative modeling of high throughput genomic data to understand the specificity and function of regulator genes in tumor development, progression, drug response and resistance. She is especially interested in genomics and bioinformatics approaches in cancer epigenetics, cancer immunology, and CRISPR screens for translational cancer research. She is the lead investigator for the Cancer Immune Data Common from NCI. She has an H-index of 79 and has published over 50 papers in Nature, Science or Cell series journals. She is the recipient of the Sloan Research Fellowship, the Richard E. Weitzman Award from the Endocrine Society, the Breast Cancer Research Foundation Investigator, and Yangtze River Scholar and 1000 Talent Scholar in China. Over the last decade, she has successfully mentored sixteen trainees to start tenure track faculty positions.

Abstract
Cancer immunotherapy has brought paradigm shifts to the treatment of cancer, but also created many challenging questions such as which patients would benefit from existing immunotherapies. Three important technologies that are under fast development will play pivotal roles in answering these important questions in cancer immunology and immunotherapy.

First, as the cost of high throughput sequencing decreases over time, tumor expression profiling is a cost effect way to characterize the tumor immune microenvironment. Second, CRISPR screen could simultaneously evaluate thousands of genes at a time on whether each gene influences how immune cells or immunotherapy drugs kill the cancer cells. Third, computational big data integration and modeling will help make sense of the data, generate novel hypothesis, and turn data into knowledge and treatment decisions.

My talk will briefly explain how immune checkpoint inhibitor works. Then it will discuss how tumor profiling, CRISPR screens, and computational data modeling could help answer questions in cancer immunotherapy, and find the best personalized combination treatment for different tumors.

abpro THERAPEUTICS

Specialize in the development of therapeutic antibodies

Abpro, Inc is a Boston based biotechnology company established in 2007. It is a global leader in therapeutic antibody discovery & development targeting cancer, autoimmune diseases and ophthalmology diseases using two proprietary platforms: DiversImmune™ and MultiMab™.

With more than ten bispecific antibody programs at different development stages, including several tetravalent bispecific T-cell engagers (TetraBi™ antibodies), Abpro is partnering with many biopharma companies in both US and China to quickly advance our pipeline into the clinic and beyond.

Contact

John Xu, 徐军

SVP of Strategic Alliance

jxu@abpro.com

Wechat 微信: elite8800

Address

68 Cummings Park Drive, Woburn Massachusetts, USA

www.abpro.com

加科思 Jacobio

公司简介

北京加科思新药研发有限公司公司致力于开发在全球拥有自主知识产权的原创新药。创立于2015年，由海归科学家王印祥博士(贝达药业Funder，国家“千人计划”专家）任董事长，美国礼来亚洲基金(Lilly Asia Ventures)、启明创投等专业基金共同投资。

公司注册在北京亦庄生医药园，拥有4000㎡新药研发实验室，内设药物设计、化学合成、药理、药物分析、药物制剂、医学部、知识产权和注册事务等新药研发相关部门，有研发人员106人。加科思的研发团队由留美海归博士和业内资深的新药研发及管理团队组成，目前已开展了多个原创新药项目的研发，主要聚焦在肿瘤治疗领域。

公司首个自主研发的原创新药JAB–3068已同时在中美提交临床试验申请，并获得美国FDA许可，在美国已经进行I期临床试验。近期将启动中国I期临床试验。

我们期待：

1.与科学家或企业广泛开展在研项目合作。

2.热情邀请海外优秀的科学家加入加科思

Discover How Cellspan ™ Implants May Significantly Improve Treatment Options for Esophageal Cancer and Atresia



biostage™

REGENERATIONS AHEAD

Biostage Is Putting Regenerative Medicine Center Stage

药明康德 WuXi AppTec

Global Platform. One Vision.



Small Molecule Drug R&D and Manufacturing



Biologics R&D and Manufacturing



Cell Therapy and Gene Therapy

Medical Device Testing

Genomics and Molecular Diagnostics

WuXi's Vision

To become the most comprehensive capability and technology platform in the global pharmaceutical and healthcare industry to fulfill the dream that "every drug can be made and every disease can be treated".

Chinese-American BioMedical Association

美中生物医药协会



CABA Mission Statement

- To promote science, technology, and business collaboration in biotech/pharmaceutical industry ;
- To build and maintain a platform through cohesive scientific, professional, and cultural connection that provides high quality services;
- To facilitate networking among scientists, professionals, and entrepreneurs in academia, biotech/pharmaceutical industry and regulatory agencies;
- To embrace advancement of science and commercialization of innovation that will benefit human health;
- To foster collaborations between the United States and China for the development of better biotech/pharmaceutical therapeutics.

About CABA

CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development. As the majority of its members are scientists with Chinese heritage, CABA will operate in two important areas. One is to serve as a platform for its members to develop and advance their careers in the US pharmaceutical and biomedical industry, the other is to serve as a bridge to connect members including corporate members with the scientific and business resources in China thus facilitating collaboration between the pharmaceutical and biomedical industries across continents. To fulfill these goals, we will organize scientific and business symposia, conferences, workshops, in US and China, as well as social events to promote networking and communication among members. We will bring together members, scientists, professionals, government officials and business leaders across the continents under a collaborative environment and achieve their best potential.

CABA is a volunteer-based society. We rely on members to contribute their time and efforts to build the organization. We rely on corporate members and sponsors to raise fund to support the above activities. We value integrity, honesty, professionalism, community service, scientific excellence, responsibility and accountability. We invite you to explore our organization, and we are confident you will share our values and are interested in becoming a member, devoting your time or efforts, or sponsoring CABA activities. In summary, CABA is built by its members and serves its members.

Contact Us

If you have any comments, suggestions or feedback to our organization and our events, please feel free to contact us at cabaconnect@gmail.com. Your comments are important for us to improve in the future. Thank you very much!

Website: www.cabaweb.org
Email: cabaconnect@gmail.com
P. O. Box 426157
Cambridge, MA 02142